ASM share buyback update May 12 – 16, 2025 Almere, The NetherlandsMay 19, 2025, 5:45 p.m. CET ASM International N.V. (Euronext Amsterdam: ASM) reports the following transactions, conducted under ASM's current share buyback program. Date Repurchased shares Average price Repurchased value May 12, 2025 2,126 € 481.32 € 1,023,285 May 14, 2025 816 € 492.00 € 401,473 May 15, 2025 3,777 € 489.70 € 1,849,592 May 16, 2025 3,246 € 491.05 € 1,593,937 Total ...
Alfen: Dead cat bounce? Ayvens: Overhang cure. Belgian telcos: Hey! discontinues €5 offer, OBEL price increases from June 2025. B&S Group: Pulls FY EBITDA guidance in light of tariffs. D'Ieteren: CMD, 1Q25 Preview. Kendrion: Wrestling through difficult macro conditions. NN Group, ASR: Vote on Dutch pension reforms postponed. TKH Group: Not that bad, good progress at Eemshaven. UCB: US Most Favoured Nation initiative back on the agenda. Vastned: Good results, integration ongoing...
ASM share buyback update May 5 – 9, 2025 Almere, The NetherlandsMay 12, 2025, 5:45 p.m. CET ASM International N.V. (Euronext Amsterdam: ASM) reports the following transactions, conducted under ASM's current share buyback program. Date Repurchased shares Average price Repurchased value May 5, 2025 3,824 € 440.73 € 1,685,336 May 6, 2025 4,694 € 431.58 € 2,025,845 May 7, 2025 4,502 € 435.59 € 1,961,005 May 8, 2025 1,758 € 453.75 € 797,695 May 9, 2025 2,802 € 452.48 € 1,267,854 Total 17,580 € 440.14 € 7,737,735 These repurchases were made as part of the €150 millio...
UCB received Japanese approval for two self-administration methods for Rystiggo (anti-FcRn) in generalised myasthenia gravis (gMG), allowing patients to use an infusion pump or manual syringe at home after training. To support the label expansion, UCB also launched a home delivery service in Japan to enhance patient convenience and satisfaction. The move aligns with Rystiggo's self-administration approval in the EU earlier this year and could support its positioning amid growing competition. We ...
Arcadis 1Q25 trading update was broadly in line. Revenues were flat organically and landed at €972m (vs. our €968m and CSS of €973m). Operating EBITA stood at €106m in line with consensus of €105m and somewhat below our €112mE. Posted margins are up 20bps in spite of flat revenue evolution. Some €21m non operating costs hit the P&L linked to restructurings and right sizing in the UK & Australian market. BtB of 1.11x (from 1.17x 1Q24) and BL of €3699m up 14% y/y and 2.8% q/q.
Ahold Delhaize: Strong 1Q25 in the US, additional details on FY25 guidance. Arcadis: Mixed start to FY25, US not to blame. PostNL: Highlights of 1Q25 analyst meeting. Sif Group: Preview - EBITDA capacity of new factory is key. Vonovia: Good results, positive message about valuations, new CEO. Wolters Kluwer: 1Q25 trading update – good start to the year
1M Performance - Absolute: During April'25 (1M period), the KBCS Holdings Universe posted a return of +2.7% which was mainly driven by multi-asset holdings (+3.0%) while single-asset holdings posted a smaller return of +2.0%. The 3 top performers during the period were D'Ieteren (+10.6%), Ackermans & van Haaren (+7.7%) and Groupe Bruxelles Lambert (+5.4%) while the 3 worst performers were Exor (-0.8%), HAL Trust (-1.5%) and Quest for Growth (-5.5%). YTD Performance - Relative: On a YTD basis (a...
Arcadis Trading Update Q1 2025: Robust performance with continued margin expansion and backlog growth PRESS RELEASE Arcadis First Quarter 2025 Trading UpdateRobust performance with continued margin expansion and backlog growth Net Revenues of €972 million, stable year-on-yearOrder Intake of €1.1 billion, resulting in record Backlog of €3.7 billion with 2.8% organic growth1) ytdOperating EBITA Margin2) expanded to 10.9% (Q1‘24: 10.7%), investments in line with strategyKUA and WSP Infrastructure Eng. GmbH acquisitions unlocking growth opportunities in GermanyOn track to achieve the st...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.